HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up
Haemonetics (HAE) reported fiscal Q1 2027 adjusted EPS of $1.14, up 3.6% and 6.5% above the Zacks consensus. Revenue rose 5.6% to $339.4 million, beating consensus. Management raised fiscal 2027 revenue guidance to 5-8% growth and organic growth to 4-7%.
How this was made
The 30-second read
Why it matters
The key tradable catalyst is the combination of an earnings and revenue beat with a raised FY2027 revenue growth range, plus improved free cash flow and modest operating margin expansion.
Market read
Traders can reprice HAE’s FY2027 growth trajectory based on the raised revenue guidance and segment momentum, with margin and cash flow details informing quality of earnings.
What to watch
The article highlights Persona PLUS adoption and yield improvements, but does not quantify sustainability of the 5%+ yield benefit or the durability of collection trends into later quarters.
Background
Haemonetics’ fiscal Q1 2027 results cover earnings, segment revenue growth (Apheresis, MedSurg), margin, and cash flow, followed by an updated full-year outlook.
Ticker impact
Haemonetics reported fiscal Q1 2027 adjusted EPS of $1.14 and raised FY2027 revenue growth guidance to 5-8% from 4-7%.
Moderately positive bias for the next few sessions as traders reprice FY2027 revenue growth and organic growth assumptions.
The article discloses a concrete earnings beat plus an explicit full-year guidance increase, alongside specific segment growth (Plasma, MedSurg) and free cash flow improvement.
Market effects
Signals continued demand strength in apheresis and MedSurg platforms, which can support sentiment for medical device peers with similar procedure-driven revenue models.
No specific regional demand shock is quantified beyond U.S. customer collections commentary.
Limited global read-through because the article emphasizes U.S. collections and product adoption timelines rather than international regulatory or reimbursement changes.
Counterpoint
Guidance is raised, but gross margin is flat and COGS rose, so upside may be capped if cost pressures persist.
Key entities
- companyHaemonetics Corporation
Subject of the article, reporting fiscal Q1 2027 results and raising fiscal 2027 revenue guidance.
- productPersona PLUS
Apheresis product rollout cited as ahead of schedule with early adopters reporting yield improvements.
